Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS Abuse Website: Has It Changed The Behavior Of Innovators?

Executive Summary

Updated numbers from the US FDA's REMS abuse website show that Celgene has received two additional safety determination letters, raising question's about whether the public list has changed the practices of brand companies hindering generic company access to samples.

Related Content

Ain’t That A Sham: US House Bill Tries To Thread The Needle On Citizen Petitions
CREATES Act Has a Penalty Problem
Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition
Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing
REMS Abuse Website: All Sizzle, No Steak?
CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor
REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
AAM, PhRMA Renew Rivalry In Hatch-Waxman Public Comments
Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts